Innovative Therapies | Transforming Lives

Kineta CEO to Speak on Immuno-oncology Panel at the BIO Investor Forum

Kineta CEO to Speak on Immuno-oncology Panel at the BIO Investor Forum

Presentation focused on the Intersection of Inflammation and Immuno-Oncology

Seattle, WA October 4, 2016 – Kineta, Inc., a biotechnology company focused on the translational development of novel antiviral and immune modulating therapies announced that its CEO, Dr. Shawn Iadonato, will participate on a panel presentation on immuno-oncology at the 15th annual BIO Investor Forum.

Dr. Iadonato will highlight Kineta’s Immuno-oncology program and be joined by leaders from other biopharmaceutical companies to discuss the development of new therapies in this emerging therapeutic area. The session entitled “The Intersection of Inflammation and Immuno-Oncology: Risks and Opportunities” is scheduled on October 18 from 9:00-10:15 PST. The conference is being held at the Westin St. Francis Hotel in San Francisco. Dr. Iadonato will be available for questions immediately following the presentation


The BIO Investor Forum is an international biotech investor conference focused on early and established private companies as well as emerging public companies. The event features plenary sessions, business roundtables and therapeutic workshops, company presentations, and One-on-One Partnering™ meetings

Kineta, Inc. is an emerging and sustainable biotech company that fills a void in the biopharmaceutical industry by efficiently advancing therapies from discovery to clinical proof of concept. We actively collaborate with a broad array of private, government and industry partners to advance our innovative research in chronic pain, immuno-oncology and infectious diseases. Kineta has established and is expanding on a diverse pipeline of novel life improving therapies that address critical unmet patient needs. For more information on Kineta, Inc. visit our website, www.Kinetabio.com

NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Kineta’s plans for pre-clinical and clinical studies, regulatory filings, and anticipated drug effects in human subjects. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta’s business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.